Reports Q1 revenue $6.96B, consensus $6.86B. "Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity," said David Ricks, Lilly’s chair and CEO. "We also announced important price reductions to make insulin more affordable and accessible for people with diabetes, as well as a significant investment in manufacturing facilities. It is an exciting year for Lilly and we look forward to delivering more medicines for unmet health needs to more people around the world."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Investors Cheer Eli Lilly’s Obesity Drug Update, Ignore Weak Earnings
- Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum
- RBC says CMS clarity on Leqembi reimbursement should reduce Biogen overhang
- LLY Earnings this Week: How Will it Perform?
- Eli Lilly Divests BAQSIMI to Amphastar for $450M